Mary Caffrey

Zanubrutinib produced prolonged progression-free survival (PFS) compared with a combination of bendamustine and rituximab among treatment-naïve patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL).

Sumit Gupta, MD, of The Hospital for Sick Children in Toronto, Canada, told attendees at the 63rd Annual American Society of Hematology Meeting that biological or genetic factors accounted for some of the gap in survival rates, but not all.

Results presented Saturday at the annual meeting of the American Society of Hematology show significant benefits in event-free survival, progression-free survival, and complete response over standard of care.

Organizers of the 63rd Annual American Society of Hematology Meeting and Exposition have multiple safety precautions in place to host a hybrid meeting in Atlanta December 11-14.

Interstitial lung disease (ILD), created by inflammation that leads to scarring of the lungs, causes shortness of breath, dry cough, and fatigue; data show it doubles mortality risk in rheumatoid arthritis (RA).

Authors from the University of Colorado say factors from skin irritations, to cost, to lack of insurance coverage, to physician barriers have limited uptake of automated insulin delivery systems.

Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.

Cynthia Rice, MPP, JDRF chief mission strategy officer, explains how Build Back Better would affect the cost of insulin.

The decision will provide Medicare coverage tests for minimal residual disease (MRD) starting December 26, 2021.

Cynthia Rice, JDRF chief mission strategy officer, discusses how JDRF is working to make automated insulin delivery available and affordable for everyone.

Zhonglin Hao, MD, PhD, of the Markey Cancer Center at the University of Kentucky, answers questions about recently approved therapies in small cell lung cancer (SCLC) and current trials examining new treatment options.

To guide its growth and its forays into home-based care, SCAN Group recently announced a Diversification Advisory Council, a group of 6 leaders from inside and outside health care with expertise in health care technology, reimbursement, and consumer engagement.

Bleeding is a risk with all antiplatelet drugs, whose effects pose a problem when patients need surgery or suffer a traumatic injury. A fast-acting reversal agent would make the drug safer to use.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, explains the interim findings of the REVERSE-IT trial that were presented at the 2021 AHA Scientific Sessions.

A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.

The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.

A wide-ranging discussion sought to bring greater urgency to achieving health equity during the 2021 American Heart Association (AHA) Scientific Sessions.

At the 2021 AHA Scientific Sessions, the lead author of DREAM-HF said evidence of the treatment's benefit among patients with elevated inflammation is positive news, and shows a need for further study.

Despite ample trial evidence that empagliflozin is effective across a broad spectrum of chronic heart failure, some doctors had been reluctant to prescribe in an acute hospital setting for safety reasons. EMPULSE findings presented at the 2021 AHA Scientific Sessions address this concern.

Cynthia Rice, JDRF chief mission strategy officer, says Medicare coverage of continuous glucose monitors (CGMs) without requiring finger sticks takes a burden off people with type 1 diabetes.

A session at the American Heart Association Scientific Sessions covered the data behind concerns about mRNA vaccines for COVID-19 and myocarditis. Then, leaders from Pfizer and Moderna discussed opportunities the technology offers.

Solutions for health equity, treatments for heart failure, and the use of technology in prevention and patient care are just some of the topics on the agenda for the 2021 American Heart Association (AHA) Scientific Sessions, which will take place Saturday through Monday in a virtual format.

Although the authors say their findings shed light on possible disruptions to insulin supply during COVID-19, they note they could not adjust for those with diabetes who died.

Joseph Mikhael, MD, of the Translational Genomics Research Institute in Phoenix, Arizona, an affiliate of City of Hope, spoke with The American Journal of Managed Care® about the increased use of triplet therapy to treat this disease.

Accomplishments such as gaining a job or completing an educational program was linked with lower depressive symptoms and undetectable viral load, independent of adherence to anti-retroviral therapy.

Tingting Tan, MD, PhD, a medical oncologist and lung cancer specialist at City of Hope, is an expert in molecular signaling pathways in tumor development and the mechanisms of chemotherapy resistance. She discussed how the treatment landscape in small cell lung cancer has shifted in the past 5 years, offering much more hope for patients.

Physician and health policy advocates praised the emphasis on streamlining models and ending silos, but practices that invested in the Oncology Care Model (OCM) await key details.